#oncology

3개의 글

July 2, 2026

141080 (LigaChem Biosciences) Stock Outlook 2026: ADC Platform Licensing Jackpot vs Lumpy Earnings

LigaChem Biosciences (KRX 141080, formerly LegoChem) stock outlook 2026: how its ADC ConjuAll linker platform, big-pharma license-out deals with partners like J&J, and Orion Group backing weigh against clinical, partner-dependency and valuation risks.

LigaChem Biosciences 141080 ADC

May 31, 2026

MCK McKesson Stock Outlook 2026: The Boring Giant Running America's Drug Supply Chain

McKesson (NYSE: MCK) is a Big Three pharmaceutical distributor with a dominant logistics moat, aggressive buybacks, and a growing oncology network. Here's the honest 2026 investment case — bull, bear, and base.

MCK McKesson pharmaceutical distribution

May 11, 2026

AZN AstraZeneca Stock Outlook 2026: Can the ADC Empire Sustain Its Momentum?

AstraZeneca (AZN) 2026 stock outlook covering Tagrisso, Enhertu, Datroway ADC pipeline, Farxiga CVRM growth, China VBP risk, and US Medicare price negotiation impact. Revenue data through Q1 2026.

AZN AstraZeneca biotech